These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 20361006)

  • 1. Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives.
    Edavalath M; Stephens JW
    Patient Prefer Adherence; 2010 Mar; 4():61-8. PubMed ID: 20361006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liraglutide: A review of its therapeutic use as a once daily GLP-1 analog for the management of type 2 diabetes mellitus.
    Dharmalingam M; Sriram U; Baruah MP
    Indian J Endocrinol Metab; 2011 Jan; 15(1):9-17. PubMed ID: 21584160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.
    Degn KB; Juhl CB; Sturis J; Jakobsen G; Brock B; Chandramouli V; Rungby J; Landau BR; Schmitz O
    Diabetes; 2004 May; 53(5):1187-94. PubMed ID: 15111485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus.
    Guyton J; Jeon M; Brooks A
    Am J Health Syst Pharm; 2019 Oct; 76(21):1739-1748. PubMed ID: 31612934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes.
    Tran KL; Park YI; Pandya S; Muliyil NJ; Jensen BD; Huynh K; Nguyen QT
    Am Health Drug Benefits; 2017 Jun; 10(4):178-188. PubMed ID: 28794822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The novel use of GLP-1 analogue and insulin combination in type 2 diabetes mellitus.
    Baruah MP; Kalra S
    Recent Pat Endocr Metab Immune Drug Discov; 2012 May; 6(2):129-35. PubMed ID: 22435393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth hormone treatment does not augment the anti-diabetic effects of liraglutide in UCD-T2DM rats.
    Swarbrick MM; Cox CL; Graham JL; Knudsen LB; Stanhope K; Raun K; Havel PJ
    Endocrinol Diabetes Metab; 2023 Jan; 6(1):e392. PubMed ID: 36480511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EADSG Guidelines: Insulin Therapy in Diabetes.
    Silver B; Ramaiya K; Andrew SB; Fredrick O; Bajaj S; Kalra S; Charlotte BM; Claudine K; Makhoba A
    Diabetes Ther; 2018 Apr; 9(2):449-492. PubMed ID: 29508275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incretin mimetics as emerging treatments for type 2 diabetes.
    Joy SV; Rodgers PT; Scates AC
    Ann Pharmacother; 2005 Jan; 39(1):110-8. PubMed ID: 15562141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics of the Glucagon-like Peptide-1 Receptor Agonist Liraglutide: A Step Towards Personalized Type 2 Diabetes Management.
    Kyriakidou A; Koufakis T; Goulis DG; Vasilopoulos Y; Zebekakis P; Kotsa K
    Curr Pharm Des; 2021; 27(8):1025-1034. PubMed ID: 33272167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.
    Flint A; Kapitza C; Hindsberger C; Zdravkovic M
    Adv Ther; 2011 Mar; 28(3):213-26. PubMed ID: 21340616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.
    Christensen M; Miossec P; Larsen BD; Werner U; Knop FK
    Expert Opin Drug Discov; 2014 Oct; 9(10):1223-51. PubMed ID: 25119443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
    Montanya E; Sesti G
    Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sitagliptin/metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy.
    Hayes J; Anderson R; Stephens JW
    Drug Des Devel Ther; 2016; 10():2263-70. PubMed ID: 27486305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide.
    Vedtofte L; Knop FK; Vilsbøll T
    Expert Rev Clin Pharmacol; 2015 May; 8(3):273-82. PubMed ID: 25816888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy.
    Meece J
    Adv Ther; 2017 Mar; 34(3):638-657. PubMed ID: 28210986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A narrative review of current trends in liraglutide: insights into the unmet needs in management of type 2 diabetes and obesity.
    Hasanzad M; Sarhangi N; Nikfar S; Ostad SN; Aghaei Meybodi HR
    J Diabetes Metab Disord; 2020 Dec; 19(2):1863-1872. PubMed ID: 33520865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus.
    Gallwitz B
    Treat Endocrinol; 2005; 4(6):361-70. PubMed ID: 16318402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.